# Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

> **NCT05430919** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 217 (actual)

## Conditions studied

- Allergic Rhinitis
- Conjunctivitis

## Interventions

- **DRUG:** REGN5713
- **DRUG:** REGN5714
- **DRUG:** REGN5715
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05430919
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-15
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430919, "Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05430919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*